Hot Topics in Diabetes: the future of antidiabetics in Australia

Report SummaryrnThe diagnosed diabetic population in Australia is growing, and patients are continuing to struggle to reach and maintain target blood glucose levels. These market drivers, combined with a preponderance of safety concerns over currently marketed antidiabetics in recent years, means that the opportunity for new and improved pipeline candidates is lucrative. Browse all: Healthcare Market Research Reports Features and benefitsrn• Provides insight into the key drivers and resistors to antidiabetic medicine uptake in Australiarn• Analyzes the current diabetes treatment paradigm in Australiarn• Assesses key brands in the insulin and non-insulin antidiabetics market in Australiarn• Summarizes key pipeline candidates expected to launch in Australia, and their likely impacts HighlightsrnDespite strong market drivers, the Australian antidiabetics market can be difficult to penetrate, with a number of leading global brands facing restrictions in approved indications and difficulties obtaining reimbursement.rnWith limited pipeline development in the insulin class, the major impact on growth will come from the biosimilar threat, expected to take effect in Australia from 2015. Meanwhile, glucagon-like peptide-1 will pick up market share if reimbursement difficulties can be resolved and as longer-acting molecules reach the Australian market.rnOral antidiabetics will continue to prosper, driven by a number of late-stage pipeline candidates, including a new class of sodium-dependent glucose transporter-2 inhibitors. However, the thiazolidinedione class is expected to lose market share to other oral antidiabetics with better long-term safety profiles. OVERVIEW OF DIABETES IN AUSTRALIArnAustralia-specific diabetes epidemiologyrnType 1 diabetes is increasing in incidence, but overall prevalence remains lowrnType 2 diabetes is highly prevalent in AustraliarnAustralian diabetes market driversrnThe prevalence of diabetes is increasing in AustraliarnHalf of all Australian diabetes patients do not reach HbA1c target of <7%rnThe Australian government has committed significant funds to diabetes research and managementrnLaunch of novel compounds will stimulate the non-insulin marketrnAustralian diabetes market resistorsrnNovel antibiotic may struggle to gain Pharmaceutical Benefits Scheme listingsrnBiosimilars will begin to impact insulin salesrnIssues with safety and efficacy of thiazolidinediones have jaded some prescribersrnHealth reforms aim to decrease the diabetes incidence and spending by increasing preventative care and chronic disease management programsrnStrategies to access the Australian antidiabetics marketrnNovo Nordisk identifies itself as a diabetes-focused company and offers support servicesrnEli Lilly needs to improve its dissemination of physician and patient educationrnMerck’s campaign promoting Januvia to GPs ensured rapid product uptake Related Reports: Autistic Disorder Therapeutics - Pipeline Assessment and Market Forecasts to 2018 Psoriasis Therapeutics - Pipeline Assessment and Market Forecasts to 2018